Investigating the Role of Epicardial Adipose Tissue in Heart Failure with Preserved Ejection Fraction: The Link to Dapagliflozin - Takeaways - MDSpire

Investigating the Role of Epicardial Adipose Tissue in Heart Failure with Preserved Ejection Fraction: The Link to Dapagliflozin

  • By

  • Aml Mohamed Soliman

  • Ramadan Ghaleb

  • Amr H. Mahmoud

  • Mustafa Al-Hassan Abdou Heidar

  • Ayman Ibrahim

  • April 22, 2026

  • 0 min

Share

  • 1

    Heart failure with preserved ejection fraction (HFpEF) is increasingly common due to rising obesity rates globally.

  • 2

    Epicardial adipose tissue (EAT) is metabolically active and contributes to myocardial remodeling and heart size increase.

  • 3

    Sodium-glucose cotransporter-2 inhibitors (SGLT2i) like Dapagliflozin may reduce EAT volume and improve outcomes in HFpEF.

  • 4

    The study involves 60 patients with LV diastolic dysfunction, assessing the impact of Dapagliflozin on EAT over six months.

  • 5

    Echocardiography and cardiac MRI will evaluate changes in EAT volume and heart function before and after treatment.

Original Source(s)

Investigating the Role of Epicardial Adipose Tissue in Heart Failure with Preserved Ejection Fraction: The Link to Dapagliflozin

  • by Aml Mohamed Soliman, Ramadan Ghaleb, Amr H. Mahmoud, Mustafa Al-Hassan Abdou Heidar, Ayman Ibrahim

  • April 22, 2026

Related Content

Cardiovascular protection by SGLT2 inhibitors: an integrative review of mechanistic networks, clinical evidence, and safety considerations

Lung ultrasound B-lines, NT-proBNP, and left atrial volume Index for bedside characterization of preserved-ejection-fraction phenotype in acute heart failure: a single-center observational study

Immune-Inflammatory markers and heart failure incidence and mortality: a population-based longitudinal study